Role of intensity-modulated radiation therapy in gastrointestinal cancer.

abstract：BACKGROUND:Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens. METHOD...

journal_title：Expert review of anticancer therapy

authors： Vincenzi B,Imperatori M,Picardi A,Vespasiani Gentilucci U,Gallo P,Fausti V,Spalato Ceruso M,Santini D,Tonini G

更新日期：2015-01-01 00:00:00

abstract：:Approximately 25% of breast cancer patients without lymph node metastases develop systemic relapse. A growing body of data supports the notion that hematogenous dissemination of breast cancer cells occurs independently of lymphatic spread of disease; however, current clinical practice does not involve routine analysis...

journal_title：Expert review of anticancer therapy

authors： Lang JE,Hall CS,Singh B,Lucci A

更新日期：2007-10-01 00:00:00

abstract：:Recent advances in molecular and cell biology have led to a greater understanding of the basic biology of bladder cancer. However, despite these advances, surgery remains a key component of modern bladder cancer treatment. Endoscopy is the mainstay of the diagnosis and treatment of superficial bladder cancer. Adjuvant...

journal_title：Expert review of anticancer therapy

authors： Wade M,Seigne JD

更新日期：2003-12-01 00:00:00

abstract：:Total mesorectal excision has been established as a standard surgical procedure for rectal cancer. MRI is now routinely used for preoperative staging of rectal cancer and provides accurate assessment of the tumor relative to the circumferential margin, that is, the mesorectal fascia. This identifies patients at risk o...

journal_title：Expert review of anticancer therapy

authors： Jhaveri KS,Sadaf A

更新日期：2009-04-01 00:00:00

abstract：:Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

journal_title：Expert review of anticancer therapy

authors： Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

更新日期：2012-06-01 00:00:00

abstract：INTRODUCTION:To date, all efforts to fight gastrointestinal cancer, regardless of its origin and entity, have resulted in complex therapeutic regimens involving a combination of systemic therapy, radiation therapy and surgery. It is generally accepted across all disciplines that not one, but the combination and the pro...

journal_title：Expert review of anticancer therapy

authors： Neumann PA,Berlet MW,Friess H

更新日期：2021-01-08 00:00:00

abstract：:While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...

journal_title：Expert review of anticancer therapy

authors： Dellinger TH,Monk BJ

更新日期：2009-07-01 00:00:00

abstract：:A lymphocele is a cystic mass that may occur in the retroperitoneum following a systematic pelvic and/or para-aortic lymphadenectomy. Lymphoceles may be the cause of severe morbidity, or rarely mortality. Symptomatic lymphoceles manifest with pain, compression of adjacent structures, lymphoedema, deep vein thrombosis ...

journal_title：Expert review of anticancer therapy

authors： Weinberger V,Cibula D,Zikan M

更新日期：2014-03-01 00:00:00

abstract：:The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been...

journal_title：Expert review of anticancer therapy

authors： Camara-Clayette V,Hermine O,Ribrag V

更新日期：2012-09-01 00:00:00

abstract：:The incidence of colorectal cancers is rising worldwide and pulmonary metastases were seen in approximately 10-15% of all patients. Surgical metastasectomy is a widely accepted procedure in selected patients and is considered as the only curative option in patients with secondary pulmonary malignancy. But surgical res...

journal_title：Expert review of anticancer therapy

authors： Limmer S,Unger L

更新日期：2011-10-01 00:00:00

abstract：:Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of these patients and is considered the standard of care. Nevertheless, 40-50% of patients have impaired renal function that p...

journal_title：Expert review of anticancer therapy

authors： Bournakis E,Dimopoulos MA,Bamias A

更新日期：2011-06-01 00:00:00

abstract：:Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma...

journal_title：Expert review of anticancer therapy

authors： Tsao CK,Gartrell BA,Oh WK,Galsky MD

更新日期：2012-12-01 00:00:00

abstract：:Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and biomarker examination of the tumor and host tissues before and af...

journal_title：Expert review of anticancer therapy

authors： Khasraw M,Bell R

更新日期：2012-08-01 00:00:00

abstract：:The incidence of thyroid cancer is increasing by 4% per year. Thyroid cancer has become the eighth most common malignancy diagnosed in women. Papillary cancer accounts for 80% of all thyroid cancer. The management of papillary thyroid cancer is challenging, primarily because there have been no prospective randomized t...

journal_title：Expert review of anticancer therapy

authors： Rosenbaum MA,McHenry CR

更新日期：2009-03-01 00:00:00

abstract：:As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for ...

journal_title：Expert review of anticancer therapy

authors： Batus M,Fidler MJ,Bonomi PD

更新日期：2010-10-01 00:00:00

abstract：:Metastasis is the spread of cells from a primary tumor to a distant site, where they arrest and grow to form a secondary tumor. Conventional metastasis models have focused primarily on analysis of end point tumor formation following inoculation with tumor cells. This approach can be used to measure the metastatic pote...

journal_title：Expert review of anticancer therapy

authors： MacDonald IC,Chambers AF

更新日期：2006-09-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

journal_title：Expert review of anticancer therapy

authors： Metro G,Crinò L

更新日期：2011-05-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far ...

journal_title：Expert review of anticancer therapy

authors： Lekakis L,de Lima M

更新日期：2008-05-01 00:00:00

abstract：:Colorectal cancer remains the second most common cause of cancer death in the USA and western Europe, with more than 34,000 new cases per year in the UK alone. Annual expenditure is in excess of pounds sterling 300 million, required for surgical, adjuvant and palliative treatment. Laparoscopic colorectal surgery has y...

journal_title：Expert review of anticancer therapy

authors： Macafee DA,Maxwell-Armstrong C,Scholefield JH

更新日期：2003-08-01 00:00:00

abstract：:Androgen receptor (AR) signaling is necessary for the development of prostate cancer. Androgen-deprivation therapy (ADT) for prostate cancer was described over 50 years ago and ADT remains the mainstay of systemic therapy. AR signaling remains intact as the disease evolves to castration-resistant prostate cancer (CRPC...

journal_title：Expert review of anticancer therapy

authors： Taplin ME

更新日期：2008-09-01 00:00:00

abstract：:Merkel cell carcinoma is an uncommon cutaneous malignancy. Although it is rare, Merkel cell carcinoma has been described as the most malignant primary skin tumor. It is therefore important that once diagnosed, Merkel cell carcinoma is treated appropriately. The aim of this short review is to provide a summary of the a...

journal_title：Expert review of anticancer therapy

authors： Plunkett TA,Subrumanian R,Leslie MD,Harper PG

更新日期：2001-10-01 00:00:00

abstract：:Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

journal_title：Expert review of anticancer therapy

authors： Sigal DS,Saven A

更新日期：2008-04-01 00:00:00

abstract：:Breast cancer represents a major health problem, with more than a million new cases and 370,000 deaths worldwide yearly. Options and understanding of how to use cytotoxic chemotherapy in both advanced and early stage breast cancer have made substantial progress in the past 10 years, with numerous landmark studies iden...

journal_title：Expert review of anticancer therapy

authors： Hussain SA,Palmer DH,Stevens A,Spooner D,Poole CJ,Rea DW

更新日期：2005-12-01 00:00:00

abstract：:Introduction: Management of clinically negative neck (cN0) in patients with parotid gland cancer is controversial. Treatment options can include observation, elective neck dissection or elective radiotherapy. Areas covered: We addressed the treatment options for cN0 patients with parotid gland cancer. A literature rev...

journal_title：Expert review of anticancer therapy

authors： Vartanian JG,Gonçalves Filho J,Kowalski LP,Shah JP,Suárez C,Rinaldo A,De Bree R,Rodrigo JP,Hamoir M,Takes RP,Mäkitie AA,Zbären P,Andreasen S,Poorten VV,Sanabria A,Hellquist H,Robbins KT,Bödeker CC,Silver C,Ferlito A

更新日期：2019-10-01 00:00:00

abstract：:The advent of granulocyte colony-stimulating factor, in particular filgrastim, in clinical use more than 10 years ago made a significant impact on the management of neutropenia and its complications. More recently, the application of pegylation technology has created a second-generation molecule, pegfilgrastim, with s...

journal_title：Expert review of anticancer therapy

authors： Ng R,Green MD

更新日期：2005-08-01 00:00:00

abstract：:With the introduction of orally-active, potent and selective third-generation aromatase inhibitors and inactivators--anastrozole, letrozole and exemestane--approaches to the treatment of advanced breast cancer are undergoing re-evaluation. In advanced breast cancer, aromatase inhibitors and inactivators are likely to ...

journal_title：Expert review of anticancer therapy

authors： Dixon JM

更新日期：2002-06-01 00:00:00

abstract：:The treatment of renal cell carcinoma is rapidly changing as a result of recent evidence concerning the efficacy of biological drugs, antiangiogenetic agents and signal-transduction inhibitors. This paper will provide a critical overview of the use of immunotherapy in renal cell carcinoma and review the available data...

journal_title：Expert review of anticancer therapy

authors： Passalacqua R,Buti S,Tomasello G,Longarini R,Brighenti M,Dalla Chiesa M

更新日期：2006-10-01 00:00:00

abstract：:Kaposi sarcoma is the most common cancer among HIV-infected individuals and one of the most common cancers in sub-Saharan Africa. Kaposi sarcoma lesions are highly vascularized, and comprised of spindle-shaped tumor cells. Kaposi sarcoma herpesvirus is etiologically linked to Kaposi sarcoma development and encodes gen...

journal_title：Expert review of anticancer therapy

authors： Hansen A,Boshoff C,Lagos D

更新日期：2007-02-01 00:00:00

abstract：BACKGROUND:Published data concerning primary mediastinal sarcomas are limited to small-sized retrospective series.  This study reviewed the clinical outcomes of these cases from the SEER (surveillance, epidemiology and end results) database. METHODS:Primary mediastinal sarcomas (1988 - 2013) were assembled from the SE...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O

更新日期：2017-11-01 00:00:00

abstract：INTRODUCTION:Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast c...

journal_title：Expert review of anticancer therapy

authors： Griguolo G,Dieci MV,Guarneri V,Conte P

更新日期：2018-06-01 00:00:00